Received Jun 27, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| RSV | RSV (AREXVY) | GLAXOSMITHKLINE BIOLOGICALS | UNK | — | — |
A patient received a dose of Arexvy after a temperature excursion.; This non-serious case was reported by a pharmacist via call center representative and described the occurrence of incorrect storage of drug in a 88-year-old male patient who received RSVPreF3 adjuvanted (Arexvy) for prophylaxis. On an unknown date, the patient received Arexvy. On an unknown date, an unknown time after receiving Arexvy, the patient experienced incorrect storage of drug (Verbatim: A patient received a dose of Arexvy after a temperature excursion.). The outcome of the incorrect storage of drug was not applicable. Additional Information: GSK Receipt Date: 18-JUN-2025 The pharmacist called to request information about the stability of Arexvy vaccines exposed to 70 degree Fahrenheit for 2 hours. No prior excursion reported. The healthcare professional wanted to know the stability information. The healthcare professional would like to know the recommendations after vaccinating two patients with Arexvy after this temperature excursion. The first patient who received the dose of Arexvy after a temperature excursion was an 88 years old male which led to incorrect storage of drug. This US2025076611 case reporter by same reporter.; Sender's Comments: US-GSK-US2025076611:same reporter